'Dr. Clifford Hudis',"'Medical Oncologist, Breast Cancer'",'MSKCC','https://www.mskcc.org/cancer-care/doctors/clifford-hudis','Head of Breast Cancer center at MSKCC'
'Dr. Heather L. McArthur',"'Medical Oncologist, Breast Cancer [Her research seems focused on HER2+ and Harmone- BC]'",'MSKCC','https://www.mskcc.org/cancer-care/doctors/heather-mcarthur','Involved in early studies re: Immunotherapy for BC'
'Yibin Kang','PROFESSOR OF MOLECULAR BIOLOGY','Princeton University','http://molbio.princeton.edu/department/honors-a-awards/63-faculty/faculty-profiles/114-kang','Included study of women from Guangzhou.  Studies biomarkers of a molecular type.  Potentially write to ask if there is opportunity to join research'
'Dr. Jennifer A. Ligibel',"'Physician, Breast Oncology | Director, Leonard P. Zakim Center for Integrative Therapies
Senior Physician'",'DFCI','http://doctors.dana-farber.org/directory/profile.asp?pict_id=0000325','Has written widely about the relationship of weight and Breast cancer recurrence.  A point of contact if you need to speak more about managing weight'
'Valerie Jansen',"'Clinical Fellow, MD'","'Vanderbilt University Medical Center Nashville, TN'",'http://www.bcrfcure.org/researchers/valerie-jansen','Studying the role of CDK4/6 inhibitors in treating ER+ progression.  Keep an eye on this person's research'
'Jack Cuzick','Professor of Epidemiology',"'Queen Mary, University of London'","'http://www.bcrfcure.org/researchers/jack-cuzick
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/abstract'","'Accomplished researcher who's led and continues to lead major clinical trials focused on following risk of recurrence in ER+ cancers.  Famous for IBIS I trial and now the IBIS III trial (""the pilot study IBIS III, a study investigating prevention of late recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment"")
""Identify risks for individual women, who have a very high or very low chance of getting breast cancer based on testing of molecular markers""'"
'David Rimm',"'Professor, Department of Pathology'",'Yale University School of Medicine','http://www.bcrfcure.org/researchers/david-rimm','Reasearches Immunotherapy for breast cancer.  Conducting studies to test a PD-1 targeting approach in breast cancer.  Most research is focused on TNBC and recently HER2.  Need to understand why ER+ is not being studied yet.  Or where it is being studied.'
'Carlos L. Arteaga',"'Director, Breast Cancer Research Program Vanderbilt-Ingram Cancer Center (VICC)'","'Vanderbilt University Medical Center Nashville, TN'",'http://www.bcrfcure.org/researchers/carlos-l-arteaga',"'Focused on ER+ BC, specifically trying to understand why ER+ tumors become resistant and is developing new approaches to improve clinical outcomes.  ""Coupling this data with genetic profiling, they have identified the gene FGFR1 as a potential therapeutic target to prevent endocrine resistance"" - keep an eye on his research'"
'Lisa A. Carey','Preyer Distinguished Professor in Breast Cancer Research','North Carolina Cancer Hospital (UNC)','http://www.bcrfcure.org/researchers/lisa-carey',"'""Dr. Carey's research is focused on understanding the impact of BC subtypes on how tumors respond to treatment"". ""In the coming year, Dr. Carey and her team will examine gene expression in 300 tumors from patients treated with tamoxifen alone to identify which gene changes may contribute to tamoxifen resistance"" - Watch very closely and see what kinds of analysis is being done and if you can participate.'"
'Sarat Chandarlapaty','Physician-scientist on ER+ BC','MSKCC','https://www.mskcc.org/research-areas/labs/sarat-chandarlapaty/overview',"'HIGHLY RELEVANT biological exploration of ER+ BC at MSKCC. Examining the significance of mutations in the estrogen receptor in cancer, identification of different means of hormone independent ER activation in cancer, development of inhibitors that potently antagonize both wild type and mutant forms of ER'"
'Saraswati Sukumar',"'Professor, Medical Oncologist (BC) / Pathologist'",'Johns Hopkins Hospita Breast Cancer Program','http://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/sukumar.html',"'""focused on using comprehensive gene expression, methylation and sequencing and metabolomics analysis to identify alterations in breast cancer, and exploiting these for early detection and therapy""
""our lab has focused on the HOX genes. HOX genes are intimately involved in the development of resistance to both chemotherapy and to agents targeting the estrogen receptor""'"
'Angela DeMichele',"'Associate Professor of Epidemiology in Biostatistics and Epidemiology
Lead of 2 - PREVENT organization'",'Upenn','https://www.pennmedicine.org/providers/profile/angela-demichele',"'Angela heads up the 2-PREVENT TCE (translational center for excellence), which is focused on understanding, preventing and treating breast cancer recurrence.  This is the only center focused on such researh.  Look for opportunities to work with this facility'"
